12:00 AM
Sep 29, 2016
 |  BC Extra  |  Company News

Catabasis, Sarepta to study DMD combination

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) gained $1.77 (40%) to $6.25 Thursday after it partnered with Sarepta Therapeutics Inc. (NASDAQ:SRPT) to study a combination...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >